OncoMatch/Clinical Trials/NCT06016179
Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer
Is NCT06016179 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Tocilizumab for malignant pleural effusion.
Treatment: Tocilizumab — The purpose of this study to find out if tocilizumab can be safely infused into chest or abdominal cavities of patients with malignancy ascites (MA) or malignant pleural effusions (MPE). Patients will have a total of 4 doses, one dose administered each week. Each dose will be greater than the previous one.
Check if I qualifyExtracted eligibility criteria
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: immunotherapy
Exception: prior immunotherapy allowed if most recent dose >30 days prior to first treatment visit
Active immunotherapy within 30 days; concurrent chemotherapy or targeted therapy is permitted but for patients with a history of prior immunotherapy, the most recent dose should be >30 days prior to the first treatment visit
Cannot have received: investigational drug
Investigational drug use within 30 days prior to first treatment dose
Lab requirements
Blood counts
Hemoglobin < 7 mg/dL; White blood cell count < 3,000/mm3; Platelet count < 70,000/mm3; Absolute neutrophil cell count < 2,000 per mm3 [excluded]
Kidney function
Creatinine > 2.5 mg/dL [excluded]
Liver function
AST/SGOT > 2 times the upper limit of normal; ALT/SGPT > 2 times the upper limit of normal; Total bilirubin > 2 times the upper limit of normal [excluded]
Laboratory abnormalities that indicate clinically significant inflammatory process AST/SGOT > 2 times the upper limit of normal ALT/SGPT > 2 times the upper limit of normal Total bilirubin > 2 times the upper limit of normal Creatinine > 2.5 mg/dL Hemoglobin < 7 mg/dL White blood cell count < 3,000/ mm3 Platelet count < 70,000/mm3 Absolute neutrophil cell count < 2,000 per mm3
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Allegheny Health Network Cancer Institute · Pittsburgh, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify